MoneyWorks4Me

Orchid Pharma gets nod from USFDA for Risedronate Sodium Tablets

14 May 2019 Evaluate

Orchid Pharma has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg. Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.

Peers
Company Name CMP
Sun Pharma. Inds. 1852.50
Dr. Reddys Labs. 1146.30
Cipla 1360.10
Lupin 2047.00
Zydus Lifesciences 1108.50
View more..